|
|
Rehydragel LV |
|
Vaxjo ID |
59 |
|
Vaccine Adjuvant Name |
Rehydragel LV |
|
Adjuvant VO ID |
VO_0001312
|
|
Description |
Rehydragel LV is a primary adjuvant in parenteral vaccine formulations, it does not generally induce cell mediated immunity (Vogel and Powell, 1995). |
|
Stage of Development |
Licensed |
|
Components |
Low viscosity aluminum hydroxide gel; crystalline aluminum oxyhydroxide AlOOH, known minerologically as boehmite. the structure consists of corrugated sheets of aluminum octahedra (Vogel and Powell, 1995). |
|
Function |
Protein binding capacity: 1.5 mg BSA/mg equivalent Al2O3 minimum. The surface area, surface charge, and morphology are major factors in its adjuvant characteristics. The use of aluminum adjuvants are accompanied by stimulation of IL-4 and stimulation of the T-helper-2 subsets in mice, with enhanced IgG1 and IgE production (Vogel and Powell, 1995). |
|
Safety |
Aluminum compounds (aluminum hydroxide, aluminum phosphate, alum) are currently the only vaccine adjuvants used in US-licensed vaccines They can induce granulomas at the inoculation site (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
